Most Recent
The Full Federal Court took a "radical" and unorthodox approach with far-reaching consequences by keeping Apple's competition dispute with Fortnite game maker Epic Games in Australia, the Silicon Valley giant has told the High Court.
Sydney's ongoing COVID-19 lockdown has created "logistical" difficulties delaying the release of a long awaited judgment in the ACCC's consumer law case against collapsed private college Phoenix Institute, which was accused of misleading students through the marketing of its courses.
Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival's claims.
Regional Express has engaged Big Six firm Clayton Utz to investigate potential court action against rival airline Qantas for alleged anticompetitive conduct.
Melbourne hospital operator Western Health has been hit with a class action on behalf of junior doctors across six hospitals in Victoria who allege they were denied pay for overtime hours, the third underpayments class action filed by doctors in the state.
A judge weighing a dispute between ASIC and the Commonwealth Bank over whether notice of a $7 million penalty should be sent out through the bank's Commbank app has questioned the usefulness of adverse publicity notices and whether they should be ditched for higher pecuniary penalties in the future.
A judge has grudgingly agreed to allow a law firm to run an investor's case against S&P Global over ratings on toxic financial products separately from a class action that makes the same claims, but was warned of the "costs consequences" of the parallel proceedings.
The a2 Milk Company has urged the Federal Court to allow its 'a2 Milk' and 'True a2' trade marks to be registered, arguing they're not merely descriptive of a protein in milk.
A Sydney law firm that brought a class action against Boston Scientific over allegedly defective pelvic mesh products has agreed to stay its case while a class action by Shine Lawyers moves ahead.
Merck Sharp & Dohme has filed a lawsuit accusing rival drug company Bristol-Myers Squibb of misusing its market power by restricting access to a treatment program for stage IV melanoma patients.